Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: A cross-sectional survey of drug using prisoners

A conservative estimate suggests that over 10.2 million people are held in penal institutions throughout the world, which equates to a world prison population of 144 per 100,000 (Walmsley, 2013). Internationally, drug dependence is common amongst prison populations and many are dependent upon heroin. A systematic review of international prevalence studies of prison populations for drug dependence found prevalence rates for drug dependence to vary from 10% to 48% in male prisoners and 30% to 60% in female prisoners (Fazel et al., 2006). (Source: Drug and Alcohol Dependence)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model.

CONCLUSIONS: Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely interventions to be developed to extend time-to-first opioid use.
PMID: 25282598 [PubMed – as supplied by publisher] (Source: Addictive Behaviors)

Table of Contents

Abstract
SAMHSA Buprenorphine Meeting: Another Step Toward Lifting the Cap
Fraud Probe of Sober Homes Highlights Drug‐Test Scams
Bill Proposed to Provide Local Incentives to Treat Addiction
N.J. Bill Would Allow Outpatient Commitment for Addiction
California Certification: CAADAC + CAARR = CCAPP
NASADAD Issues Public Policy Statement Endorsing Naloxone
ASAM Revises Public Policy Statement on Naloxone
Methadone Patient on the Pain of Stigma
Coming up (Source: Alcoholism and Drug Abuse Weekly)

Table of Contents

Abstract
SAMHSA Buprenorphine Meeting: Another Step Toward Lifting the Cap
Fraud Probe of Sober Homes Highlights Drug‐Test Scams
Bill Proposed to Provide Local Incentives to Treat Addiction
N.J. Bill Would Allow Outpatient Commitment for Addiction
California Certification: CAADAC + CAARR = CCAPP
NASADAD Issues Public Policy Statement Endorsing Naloxone
ASAM Revises Public Policy Statement on Naloxone
Methadone Patient on the Pain of Stigma
Coming up (Source: Alcoholism and Drug Abuse Weekly)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders

Individuals with alcohol and/or drug use disorders often fail to receive care, or evidence‐based care, yet the literature shows health economic benefits. Comparative effectiveness research is emerging that examines approved approaches in terms of real, total healthcare cost/utilization. Comprehensive retrospective insurance claims analyses are few but tend to be nationally distributed and large. The emerging pattern is that, while treatment in general is cost effective, specific therapeutics can yield different health economic outcomes. Cost/utilization data consistently show greater savings with pharmacotherapies (despite their costs) versus psychosocial treatment alone. All FDA‐approved addiction pharmacotherapies (oral naltrexone, extended‐release naltrexone, acamprosate, disulfir…

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Factors Affecting Noncompliance With Buprenorphine Maintenance Treatment

Conclusions:Patients founds to be noncompliant were more likely to suffer from comorbid psychiatric illness. Patients who tested positive for benzodiazepines or cannabis were more likely to be noncompliant with treatment. Although the rate of noncompliance (inaccurate pill count) was high, patients were still found to be taking their prescribed buprenorphine as evidenced by positive UDS for buprenorphine/norbuprenorphine. In addition, our sample had a high rate of negative UDS screens for opioids and cocaine. (Source: Journal of Addiction Medicine)